Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

BACKGROUND: Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA. CASE PRESENTATION: A 78-year-old asymptomatic man with PHA that was successfully...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Yu, Yang, Jihong, Liu, Lili, Zeng, Yixin, Ma, Jie, Jia, Jing, Zhang, Li, Li, Xiaoguang, Wu, Peihong, Wang, Wenchao, Liu, Dongge, Chen, Huan, Zhao, Yunbo, Xi, Huan, Wang, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822655/
https://www.ncbi.nlm.nih.gov/pubmed/29466964
http://dx.doi.org/10.1186/s12885-018-3996-3
_version_ 1783301734881296384
author Qiao, Yu
Yang, Jihong
Liu, Lili
Zeng, Yixin
Ma, Jie
Jia, Jing
Zhang, Li
Li, Xiaoguang
Wu, Peihong
Wang, Wenchao
Liu, Dongge
Chen, Huan
Zhao, Yunbo
Xi, Huan
Wang, Yao
author_facet Qiao, Yu
Yang, Jihong
Liu, Lili
Zeng, Yixin
Ma, Jie
Jia, Jing
Zhang, Li
Li, Xiaoguang
Wu, Peihong
Wang, Wenchao
Liu, Dongge
Chen, Huan
Zhao, Yunbo
Xi, Huan
Wang, Yao
author_sort Qiao, Yu
collection PubMed
description BACKGROUND: Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA. CASE PRESENTATION: A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor. CONCLUSION: Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA.
format Online
Article
Text
id pubmed-5822655
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58226552018-02-26 Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report Qiao, Yu Yang, Jihong Liu, Lili Zeng, Yixin Ma, Jie Jia, Jing Zhang, Li Li, Xiaoguang Wu, Peihong Wang, Wenchao Liu, Dongge Chen, Huan Zhao, Yunbo Xi, Huan Wang, Yao BMC Cancer Case Report BACKGROUND: Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA. CASE PRESENTATION: A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor. CONCLUSION: Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA. BioMed Central 2018-02-21 /pmc/articles/PMC5822655/ /pubmed/29466964 http://dx.doi.org/10.1186/s12885-018-3996-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Qiao, Yu
Yang, Jihong
Liu, Lili
Zeng, Yixin
Ma, Jie
Jia, Jing
Zhang, Li
Li, Xiaoguang
Wu, Peihong
Wang, Wenchao
Liu, Dongge
Chen, Huan
Zhao, Yunbo
Xi, Huan
Wang, Yao
Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report
title Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report
title_full Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report
title_fullStr Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report
title_full_unstemmed Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report
title_short Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report
title_sort successful treatment with pazopanib plus pd-1 inhibitor and rak cells for advanced primary hepatic angiosarcoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822655/
https://www.ncbi.nlm.nih.gov/pubmed/29466964
http://dx.doi.org/10.1186/s12885-018-3996-3
work_keys_str_mv AT qiaoyu successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT yangjihong successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT liulili successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT zengyixin successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT majie successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT jiajing successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT zhangli successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT lixiaoguang successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT wupeihong successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT wangwenchao successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT liudongge successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT chenhuan successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT zhaoyunbo successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT xihuan successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport
AT wangyao successfultreatmentwithpazopanibpluspd1inhibitorandrakcellsforadvancedprimaryhepaticangiosarcomaacasereport

Ejemplares similares